TG Therapeutics, Inc. (TGTX) Q2 FY26 Earnings Call

Approximately $228 million in Q2 U.S. revenue grew 64% year over year, and 2026 guidance rose to $890-$905 million.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-03
Length49 minutes
EPS$0.05
Revenue$240.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25 · Q2 FY25

Read the full Q2 FY26 earnings call transcript

All TGTX earnings · Back to TGTX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.